RESEARCH ARTICLE

CMR feature tracking in cardiac asymptomatic systemic sclerosis: Clinical implications

Konstantinos Bratis1‡, Anthony Lindholm2‡, Roger Hesselstrand3, Häkan Arheden2, Georgia Karabela4, Efthymios Stavropoulos4, Gikas Katsifis4, Genovefa Kolovou1, George D. Kitas5, Petros P. Sfikakis6, Loukia Koutsogeorgopoulou7, Sophie Mavrogeni1, Ellen Ostenfeld2*

1 CMR Unit, Onassis Cardiac Surgery Centre, Athens, Greece, 2 Department of Clinical Sciences, Clinical Physiology, Skåne University Hospital, Lund University, Lund, Sweden, 3 Department of Clinical Sciences, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, 4 Naval Hospital, Athens, Greece, 5 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 6 First Department of Prophylactic and Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 7 Pathophysiology Department, Laikon Hospital, Athens, Greece

☯ These authors contributed equally to this work.
‡ These authors are first co-authors on this work.
* ellen.ostenfeld@med.lu.se

Abstract

Background

Impaired myocardial deformation has been sporadically described in cardiac asymptomatic systemic sclerosis (SSc). We aimed to study myocardial deformation indices in cardiac asymptomatic SSc patients using cardiac magnetic resonance feature tracking (CMR-FT) and correlate these findings to the phenotypic and autoimmune background.

Methods

Fifty-four cardiac asymptomatic SSc patients (44 females, 56±13 years), with normal routine cardiac assessment and CMR evaluation, including cine and late gadolinium enhancement (LGE) images, were included. SSc patients were compared to 21 sex- and age- matched healthy controls (17 females; 54±19 years). For CMR-FT analysis, a mid-ventricular slice for LV peak systolic radial and circumferential strain and a 4-chamber view for LV/RV peak systolic longitudinal strain were used.

Results

Twenty-four patients had diffuse cutaneous SSc and 30 limited cutaneous SSc. Thirteen patients had digital ulcers. Median disease duration was 3.6 years. LV ejection fraction was higher in SSc patients compared to controls (62±6% vs. 59±5%, p = 0.01). Four patients had no LGE examination; in the remaining patients LGE was absent in 74%, while 18% had RV insertion fibrosis and 8% evidence of subendocardial infarction. LV longitudinal strain differed in those with insertion fibrosis (-18.0%) and infarction (-16.7%) compared to no fibrosis (-20.3%, p = 0.04). Patients with SSc had lower RV longitudinal strain and strain...
rate compared to controls (p<0.001 and p = 0.01, respectively). All other strain and strain rate measurements were non-significant between patients and controls.

Conclusions
In cardiac asymptomatic SSc patients with normal routine functional indices, CMR-FT identifies subclinical presence of insertion fibrosis and/or myocardial infarction by impaired LV longitudinal strain. RV derived longitudinal indices were impaired in the patient group. CMR FT indices did not correlate to the patients’ phenotypic and autoimmune features.

1. Introduction
The heart is a major target organ in systemic sclerosis (SSc), appearing to be involved in 12–80% of autopsy studies [1], although the involvement is often clinically silent [2] and is recognized only in 15–25% [3, 4]. Myocardial disease is complex and dynamic and includes myositis, characterized by immune-mediated myopericardial inflammation [5, 6], microvascular dysfunction [7–10] and fibrosis [4] predisposing to cardiac dysfunction and failure, coronary artery disease, conduction system abnormalities and pericardial disease [11]. All subtypes of SSc are at risk for significant heart disease, but patients with rapidly evolving diffuse skin disease [12] as well as those with underlying skeletal muscle disease [13, 14] are prone to develop severe cardiomyopathy. Cardiac involvement carries an ominous prognosis, irrespective of the clinical presentation [15]. Early detection allows to timely start an immunosuppressive treatment and possibly prevent cardiac damage progression [16].

Cardiovascular magnetic resonance (CMR) is an accurate method for non-invasive, non-radiating assessment of ventricular volumes, function, myocardial perfusion as well as tissue characterization [17]. While ejection fraction is of prognostic value, it is a crude measure of subtle myocardial changes. Feature tracking derived from CMR cine images (CMR-FT) offers quantitative assessment of the myocardial deformation, beyond global assessment with ejection fraction and before other recognized markers [18, 19].

In the setting of SSc, there is only limited data [20] examining CMR derived left (LV) and right ventricular (RV) deformation indices in patients with SSc compared to healthy controls and their relationship to clinical subsets (diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc)) and other disease features (presence of digital ulcers, disease duration, antibody subset). The aims of this study were 1) to investigate if LV longitudinal, radial and circumferential as well as RV longitudinal strain differ in cardiac asymptomatic SSc patients with preserved ejection fraction and normal estimated pulmonary pressure compared to healthy controls, 2) to correlate the LV and RV deformation indices to clinical subsets (lcSSc vs dcSSc) and other disease characteristics (digital ulcers, autoimmune profile, disease duration, unknown myocardial fibrosis) and assess its potential clinical value.

2. Materials and methods
2.1. Patients and controls
The study was conducted at Skåne University Hospital, Lund, Sweden and Onassis Cardiac Surgery Centre, Athens, Greece and patients were included from both hospitals. Patients fulfilling the American College of Rheumatology criteria [21] and/or LeRoy’s classification criteria for the diagnosis of SSc [22], who were prospectively included in prior studies from
our groups [17, 23, 24] and had undergone a CMR exam were retrospectively included and analysed provided they had normal routine cardiac assessment and no cardiac symptoms. Exclusion criteria were known heart disease, renal failure, pulmonary hypertension and contraindications to CMR.

Medical records were reviewed to collect clinical characteristics of the patients. Detailed history, physical examination, routine laboratory investigations, autoimmune screening as well as screening for atherosclerotic disease risk factors were assessed in all patients. For subgroup analyses, patients were divided based on the observation time from SSc diagnosis to CMR examination (disease duration), skin involvement (lcSSc vs dcSSc), presence of digital ulcers and autoimmune profile [anti centromerantibodies (ACA), anti-nuclear antibodies (ANA), anti RNA polymerase III antibodies (ARA), anti-topoisomerase I antibodies (ATA)]. SSc patients were compared with sex-matched healthy controls that underwent cine CMR evaluation during the same period. Controls were prospectively enrolled in previous study from the Lund group [25] and were matched with the patient population for sex and age, as LV strain with CMR has been shown to be sex dependent [26]. Controls were checked for and had no cardiac morbidities, medical history or medication and were examined by clinicians before their study enrollment.

This study was approved by the ethics committees of Skåne University Hospital, Lund, Sweden and Onassis Cardiac Surgery Centre, Athens, Greece in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Informed written consent was obtained from patients and healthy controls.

2.2. CMR protocol

CMR was performed on a 1.5 Tesla scanner using ECG-triggered cine steady-state free precession breath-hold cine long-axis planes and sequential 8 mm short-axis slices including the atrioventricular ring to the apex to assess ventricular function. Typical image parameters were: echo time (TE) 1.4–1.6, repetition time (TR) 2.8–3.2 ms, flip angle 60˚ and gap 0 mm (Achieva, Philips Medical Healthcare, Best, the Netherlands), 2 mm (Aera, Siemens, Erlangen, Germany) and 3 mm (GE hdxt 1.5 T, version 16, GE Healthcare, Milwaukee, WI, USA).

To assess for fibrosis, late gadolinium enhanced (LGE) images were acquired 10–15 minutes after intravenous administration of gadolinium-DOTA (Dotarem, Guerbet, Roissy, France; 0.2mmol/kg) in identical short-axis planes using an inversion-recovery gradient echo sequence for fibrosis detection. Inversion times were adjusted to null normal myocardium.

2.3. CMR image analysis

CMR studies were analysed with Circle cmr® 5.3.4 Tissue-Tracking Plugin (Circle Cardiovascular Imaging Inc., Calgary, AB, Canada) in a random order blinded to the patient clinical characteristics (A.L.). Cine short axis was used to evaluate LV and RV ejection fractions (EF). Analyses of myocardial deformation from two-dimensional strain and strain rate data were performed using feature-tracking imaging. Peak systolic LV and RV longitudinal myocardial deformation were measured in the left 4-chamber view (Fig 1). LV longitudinal deformation was the average of 7 segments, while the RV deformation was the average of RV free wall alone. Peak systolic LV radial and circumferential deformation indices were measured in LV short axis view at the mid ventricular level and were expressed as the average of six segments. The intrinsically negative measured data were converted to absolute values. In case of misalignment, an experienced observer acted as a blinded independent adjudicator (E.O.). For interobserver variability second observer (K.B.) blinded to prior data analyzed deformation indices on 15 individuals (10 patients and 5 controls). The evaluation of scar tissue was
performed visually from the late gadolinium enhancement images (E.O.) and was categorized as absent LGE, fibrosis at RV insertion and subendocardial or transmural infarction.

2.4. Estimation of pulmonary pressure
Echocardiography was performed on clinical indication and/or as screening for pulmonary arterial hypertension. Pulmonary pressure was estimated from trans-tricuspid regurgitation with maximum velocity (TRVmax). TRVmax ≤ 2.8 m/s was considered normal estimated pulmonary pressure, while TRVmax > 2.8 m/s giving rise to suspected elevated pressure [27]. Patients with suspected elevated pressure had invasive right heart catheterisation performed by clinical indication. Mean pulmonary arterial pressure ≥25 mmHg was considered elevated [28] and patients with increased pulmonary pressure were not included.

2.5. Statistical analysis
All data are reported as mean ± SD. Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA, version 23.0). Correlation analysis was assessed using Pearson’s correlation. Volumetric measurements were normalized to the body surface area. Chi-square and unpaired student t tests were used to compare groups. ANOVA was used to test differences among groups. Mean ± SD was calculated to study the variability of the measurements. Inter-observer variability was assessed using intra class correlation coefficient. Results with a p-value of < 0.05 were considered statistically significant.

3. Results
3.1. Patient and controls
Fifty-four cardiac asymptomatic SSc patients (44 females, aged 56 ± 13 years) with no known cardiac involvement were retrospectively enrolled into the study. Twenty-one age- and
gender- matched healthy controls were used for comparison [25]. Demographic characteristics are shown in Table 1. CMR functional characteristics of the included patients and control subjects are shown in Table 2.

Twenty-four patients were diagnosed as having dcSSc and 30 as having lcSSc. Digital ulcers were registered on 13 patients and 41 did not have digital ulcers. Nineteen patients had anti centromere antibodies (ACA), 18 had anti topoisomerase I antibodies (ATA), 4 had anti RNA polymerase III antibodies (ARA), 10 had anti-nuclear antibodies without ACA, ARA or ATA (ANA+) and 3 were ANA-negative (ANA-). Patients had mean disease duration (time of observation from SSc diagnosis to CMR examination) of 43 months (range 6.6–311 months).

Four patients had LGE pattern consistent with myocardial infarction (2 had subendocardial and 2 had transmural infarction) of which only one had prior suspected ischemic heart disease and 9 had fibrosis at RV insertion, leaving 37 patients without visually localized fibrosis and

Table 1. Patient characteristics.

|                      | Controls (n = 21) | SSc (n = 54) | P-value |
|----------------------|------------------|--------------|---------|
| **Sex (female)**     | 17 (80%)         | 44 (81%)     | 1.0     |
| **Age (years)**      | 54±19            | 56±13        | 0.8     |
| **BSA (m²)**         | 1.8±0.2          | 1.8±0.2      | 0.7     |
| **Heart rate (bpm)** | 63±8             | 79±79        | <0.001  |

**CMR**

|                      |                  |              |         |
|----------------------|------------------|--------------|---------|
| Fibrosis/infarction  | n/a              | 9 (18%) / 4 (8%) | n/a     |
| LV mass              | 79±19            | 84±27        | 0.4     |

**SSc Phenotype**

|                      |                  |              |         |
|----------------------|------------------|--------------|---------|
| SSc-duration (months)| n/a              | 43±70        | n/a     |
| mRSS                 | n/a              | 5±8          | n/a     |
| Raynaud’s            | n/a              | 48 (89%)     | n/a     |
| SSc-type (diffuse/limited) | n/a        | 24 (44%) / 30 (56%) | n/a |
| Digital ulcer        | n/a              | 13 (24%)     | n/a     |

**Comorbidities**

|                      |                  |              |         |
|----------------------|------------------|--------------|---------|
| Smoker (yes/ex)      | n/a              | 7 (13%) / 11 (20%) | n/a   |
| Diabetes             | n/a              | 9 (17%)      | n/a     |
| COPD/Emphysema       | n/a              | 11 (20%)     | n/a     |
| Hypertension         | n/a              | 8 (15%)      | n/a     |
| Known IHD            | n/a              | 1 (2%)       | n/a     |

**Medication**

|                      |                  |              |         |
|----------------------|------------------|--------------|---------|
| ACE/ARB              | n/a              | 12(22%)      | n/a     |
| CCB                  | n/a              | 27(50%)      | n/a     |
| BB                   | n/a              | 2(4%)        | n/a     |
| Statin               | n/a              | 11(20%)      | n/a     |
| NSAID                | n/a              | 13(24%)      | n/a     |
| Corticosteroid       | n/a              | 12(22%)      | n/a     |
| Immunosuppressant    | n/a              | 11(20%)      | n/a     |

Expressed as mean±SD or absolute numbers with percentage in parenthesis.

Control = Healthy adult volunteers; SSc = Systemic sclerosis; BSA = Body surface area; LV mass = Left ventricular mass; CMR = Cardiac magnetic resonance; mRSS = Modified Rodnan skin score; COPD = Chronic obstructive pulmonary disease; IHD = Ischemic heart disease; SSc-duration in years; ACE/ARB = Ace inhibitor/Angiotensin II blocker; CCB = Calcium channel blocker; BB = Beta-blocker; ERA = Endothelin-receptor antagonists; PDEI5 = Phosphodiesterase type 5 inhibitor; NSAID = Non-steroidal anti-inflammatory drugs, n/a = not applicable

https://doi.org/10.1371/journal.pone.0221021.t001
Table 2. Cardiac magnetic resonance (CMR) functional, volumetric and myocardial deformation data in healthy adult volunteers (control), systemic sclerosis (SSc) patients and subgroups (diffuse and limited cutaneous systemic sclerosis (SSc) patients, SSc patients with and without digital ulcers).

|                          | Controls (n = 21) | SSc (n = 54) | P-valueA | Diffuse SSc (n = 24) | Limited SSc (n = 30) | P-valueB | No Digital Ulcer (n = 41) | Digital Ulcer (n = 13) | P-valueC |
|--------------------------|------------------|--------------|----------|----------------------|----------------------|----------|--------------------------|------------------------|----------|
| **Left ventricle**       |                  |              |          |                      |                      |          |                          |                        |          |
| LVEF (%)                 | 59±5             | 62±6         | 0.01     | 63±5                 | 62±7                 | 0.4      | 61±6                     | 65±3                   | 0.02     |
| LVEDV (ml)               | 156±26           | 131±28       | 0.001    | 131±25               | 131±30               | 0.8      | 132±28                   | 129±26                 | 0.7      |
| LVESV (ml)               | 65±14            | 50±15        | < 0.001  | 49±12                | 51±16                | 0.7      | 51±15                    | 46±11                  | 0.2      |
| LSV (ml)                 | 89±17            | 79±17        | 0.04     | 84±13                | 78±18                | 0.3      | 79±17                    | 83±17                  | 0.5      |
| Strain (Mid radial)      | 44.5±8.5 (n = 19)D | 42.2±11.8 (n = 52)E | 0.4 | 38.7±12.2 (n = 22) | 44.8±11.0 (n = 19) | 0.07 | 43.4±12 (n = 11) | 37.9±11 (n = 11) | 0.2 |
| Strain rate (Mid radial) | 2.4±0.72 (n = 19) | 2.5±0.82 (n = 47)F | 0.7 | 2.3±0.75 (n = 17) | 2.6±0.85 (n = 19) | 0.2 | 2.5±0.80 (n = 38) | 2.3±0.91 (n = 9) | 0.3 |
| Strain (Mid circumferential) | -21.9±2.8 (n = 19)D | -21.6±3.2 (n = 52)E | 0.7 | -20.9±3.7 (n = 22) | -22.1±3.0 (n = 19) | 0.2 | 22.1±3.0 (n = 11) | -19.7±3.4 (n = 11) | 0.02 |
| Strain rate (Mid circumferential) | -1.0±0.57 (n = 19)D | -1.3±0.37 (n = 47)F | 0.07 | -1.2±0.42 (n = 17) | -1.3±0.34 (n = 19) | 0.6 | 1.3±0.37 (n = 38) | -1.1±0.34 (n = 9) | 0.1 |
| Strain (Longitudinal)    | -20.3±2.5        | -19.4±3.2    | 0.3      | -18.9±2.9            | -19.8±3.4            | 0.3 | 19.7±3.1                 | -18.8±3.4             | 0.4 |
| Strain rate (Longitudinal) | -1.1±0.21 (n = 19) | -1.2±0.35 (n = 49)G | 0.5 | -1.1±0.36 (n = 19) | 1.1±0.28 (n = 19) | 0.6 | 1.1±0.32 (n = 38) | -1.1±0.29 (n = 11) | 0.5 |
| **Right ventricle**      |                  |              |          |                      |                      |          |                          |                        |          |
| RVEF (%)                 | 58±6             | 59±9         | 0.8      | 56±10                | 60±7                 | 0.08     | 59±7                     | 57±12                  | 0.4      |
| RVEDV (ml)               | 164±34           | 129±37       | < 0.001  | 131±49               | 127±25               | 0.7      | 133±39                   | 115±31                 | 0.1      |
| RVESV (ml)               | 68±19            | 54±26        | 0.04     | 59±35                | 51±16                | 0.3      | 56±26                    | 50±25                  | 0.5      |
| RVSV (ml)                | 94±23            | 74±17        | < 0.001  | 72±20                | 76±15                | 0.4      | 77±16                    | 65±18                  | 0.03     |
| Strain (Longitudinal)    | -28.2±2.0 (n = 20)H | -27.0±4.0 (n = 20)I | 0.01 | -25.9±4.4            | -27.9±3.4            | 0.07 | 27.4±3.9                 | -26.0±4.2             | 0.3 |

Strain is measured in (%), Strain rate is measured in (1/s) expressed in mean±SD.

A: controls versus all SSc,
B: diffuse versus limited cutaneous SSc,
C: without versus with digital ulcers.
D: Two controls had inadequate image acquisition for radial and circumferential tracking,
E: Two patients had artefacts,
F: 7 had no time data for strain rate analysis in short axis images,
G: Five patients had not time data for strain rate analysis in 4-chamber view,
H: One control had inadequate tracking for RV strain analysis.

Control = Healthy adult volunteers; SSc = Systemic sclerosis; LVEF = Left ventricular ejection fraction; LVEDV = Left ventricular end diastolic volume; LVESV = Left ventricular end systolic volume; LSV = Left ventricular stroke volume; RVEF = Right ventricular ejection fraction; RVEDV = Right ventricular end diastolic volume; RVESV = Right ventricular end systolic volume; RVSV = Right ventricular stroke volume.

https://doi.org/10.1371/journal.pone.0221021.t002

scar. Four patients had no gadolinium administration due to impaired kidney function (n = 1), anxiety/claustraphobia ending the examination (n = 2) or declining to receive gadolinium (n = 1).

3.2. CMR-FT results

3.2.1. Myocardial deformation analysis in SSc patients compared to controls. Patients with SSc had lower RV longitudinal strain and strain rate compared to controls (p<0.001 and p = 0.01, respectively). All other strain and strain rate measurements were non-significant between patients and controls (Table 2).
When evaluating skin involvement, all strain and strain rate measurements were non-significant between patients with lcSSc, dcSSc or healthy controls (Table 2).

When evaluating severe microvascular involvement of the skin, all strain measurements, except LV mid circumferential strain (p = 0.02), were non-significant between patients with or without digital ulcers (Table 2).

LV longitudinal strain was lower in patients with insertion fibrosis (-18.0%) and even lower in patients with infarction (-16.6%) compared to those without fibrosis (-20.3%, p = 0.04 among the groups). LVEF, LV radial and circumferential strain as well as RV longitudinal strain did not differ among the groups. However, RVEF was lower in patients with fibrosis and infarction (Table 3).

In disease duration correlation analysis, all correlations between disease duration and strain and strain rate measurements were non-significant (LV longitudinal strain, p = 0.8; RV longitudinal strain, p = 0.2; LV mid radial strain, p = 0.7; LV mid circumferential strain, p = 0.6; LV longitudinal strain rate, p = 0.7; LV mid radial strain rate, p = 0.3; LV mid circumferential strain rate, p = 0.5).

All strain and strain rate measurement, except LV longitudinal strain rate (p = 0.04), were non-significant when comparing groups of autoantibodies ACA, ARA, ATA, ANA+ or ANA (LV longitudinal strain, p = 0.9; LV mid radial strain, p = 0.3; LV mid circumferential strain, p = 0.08; LV mid radial strain rate, p = 0.6; LV mid circumferential strain rate, p = 0.4; RV longitudinal strain, p = 0.1).

3.2.2. Variability. Intra-class correlation in inter-observer variability was <0.5 for LV longitudinal strain, RV longitudinal strain, LV radial strain and LV circumferential strain.

### 4. Discussion

In this CMR study, early cardiac involvement in cardiac asymptomatic SSc patients was documented in the RV but not in the LV. SSc patients had smaller LV/RV volumes as well as higher LVEF, but no difference in radial, circumferential or longitudinal indices, compared with age- and gender-matched healthy controls. Thirteen out of fifty SSc patients had insertion fibrosis and/or infarction, detected due to lower LV longitudinal strain, compared with those without. Finally, LV circumferential strain and LVEF were higher in SSc without, compared with those with digital ulcers.
The finding of smaller LV and RV volumes and higher LVEF could be related to heart rate. Interestingly, LV mass was not significantly different between patients and controls. SSc patients have higher heart rate than normal controls, and autonomic dysfunction with altered diastolic function and cardiac remodeling in SSc has been suggested [29]. Furthermore, vasoactive calcium channel blockers (such as the often used Nifedipine) can induce increased heart rate as a reflection of the sympathetic nervous system of vasodilatation [30]. With 50% of patients having calcium channel blockers, in our study, both SSc in itself and calcium channel blockers can cause higher heart rate. A higher heart rate decreases the diastolic filling, and this could affect the volumes and function [31]. Lastly, diffuse fibrosis could stiffen the myocardium and leads to decrease the ventricular volumes, leading to increased LVEF. In a recent study by Hromadka et al. on SSc patients [32] the conventional echocardiography parameters were similar in SSc patients and controls. However, the global longitudinal peak systolic strain (GLPS) was lower in SSc patients compared to controls and correlated negatively with native T1 [30]. In our study, ventricular volumes and detection of local fibrosis were in parity with the echocardiographic results. However, in the latter study no subclinical infarction was reported.

Global longitudinal strain has an important role in identifying early myocardial dysfunction in patients with non-ischemic cardiomyopathies [33, 34]. However, in the majority of our patients left ventricular indices were not different in SSc compared to controls. This is potentially due to the selection of asymptomatic patients in which the purpose of our study was to find subclinical manifestations. Our results were in agreement with recent data showing subclinical CMR-derived myocardial deformation abnormalities in SSc patients, due to underlying fibrosis or infarction, as assessed by LGE [20], as well as parametric imaging [35]. Furthermore, LGE was significantly associated with circumferential and radial strain that is also in agreement with our results. The early detection of cardiac involvement in SSc could allow timely redirection of the management of these patients and potentially prevent the progression to cardiac damage with improved quality of life and longevity, underscoring the potential value of CMR-FT in identifying cardiac involvement in this cohort of patients.

Right ventricular deformation indices were significantly impaired in the patients’ group. SSc patients are prone to develop pulmonary hypertension and early RV involvement should always be suspected in this population. Our results are in agreement with previous echocardiography derived ones identifying early-stage impaired myocardial deformation. [36] Defining early markers of impaired RV function is crucial and may constitute a potential target for early intervention.

We aimed further to examine the potential correlation of myocardial deformation to the underlying SSc clinical status and autoimmune profile. It has been documented that cardiac manifestations occur earlier and more frequently in patients affected by dcSSc than with lcSSc [37]. Patients with lcSSc or dcSSc are characterized by clinically evident inflammatory and fibrotic processes of the skin, especially those with ARA. These mechanisms also play a major role in cardiac involvement leading to various clinical manifestations including heart failure, arrhythmias and pulmonary hypertension. Patients with dcSSc are at higher risk to develop cardiac involvement than those with lcSSc [38, 39]. However, in our study, the lack of differences between patients with lcSSc and dcSSc are consistent with a previous study in which cardiac symptoms were not found to be significantly different with the use of echocardiography derived indices between the two subtypes [40].

There were no major differences in strain among patients with different autoantibody profile. So far, there has been conflicting data in the literature whether strain is altered in patients with different phenotypes of autoantibodies [36, 39, 41]. Further large-scale research is required to offer more insight on the relative myocardial involvement in these subgroups of patients. After all, in the present study, the subgroups were rather small.
From a technical perspective, our strain measurements were expressed as the fractional change in the length (as a percentage) from the resting state (end diastole) to the state following myocardial contraction [42]. Strain analysis using this feature tracking method [43] is as feasible for the assessment of non-tagged SSFP cine CMR as for tagging CMR, indicating a unique new approach for comprehensive clinical assessment of regional cardiac function [44]. Tracking techniques have been reported more robust and reproducible [45] for global rather than regional values [46, 47].

Both echocardiography and CMR currently offer reproducible measurements of global strain values that can be applied in different clinical scenarios to assess LV and RV function [48]. CMR has an established and continuously expanding role in tissue characterization and is the modality of choice for accurate evaluation of global function using volumetric assessment. The additional value of myocardial deformation information beyond direct tissue characterization remains to be evaluated. A reliable segmental analysis is expected to render the technique clinically meaningful.

5. Limitations of the study

Limitations of the study were:

1. The use of multiple scanners and effects on variability of CMR measurements. From echocardiography, examining the same patient with two echo machines from different vendors can generate different strain values even when images are interpreted with the same software [49] and analysis software from different vendors can generate different strain values even from the same image data set. [50] However, we used the same software and multivendor comparison for CMR strain analysis are not available yet. Multicenter studies with multivendor assessment of LGE and myocardial at risk has been published [51] why we consider the assessment of fibrosis from three vendors as a minor limitation.

2. Our study included mainly long-term SSc cardiac asymptomatic patients with a median time of 3.6 years from diagnosis. Therefore, part of the included patients had already received potentially cardiotoxic disease-modifying agents.

3. Our CMR protocol included only functional assessment as well as visual detection of focal replacement fibrosis. Parametric imaging, which is currently the most sensitive index for detection of diffuse myocardial fibrosis, irrespective of LGE, was not included in the protocol. Perfusion imaging has been the subject of previous studies by some of the authors. [17]

4. The sample size of the patient group is small but comparable to number of patients traditionally used in similar studies, given the rare nature of the entity. The control group was matched with the patient population for sex and age, although LV strain with CMR has been shown to be only sex dependent, in order to achieve the maximal accordance between the two groups.

6. Conclusion

A comprehensive biventricular myocardial deformation study with CMR feature tracking and LGE reveals early subclinical cardiac involvement in cardiac asymptomatic SSC with normal routine cardiac evaluation. CMR-FT contributed to differentiate the patients with silent myocardial necrosis as well as identified early RV involvement. The clinical significance of CMR deformation abnormalities for outcome and treatment goals remains to be elucidated through multicenter longitudinal studies.
Author Contributions

Conceptualization: Konstantinos Bratis, Håkan Arheden, Genovefa Kolovou, Sophie Mavrogeni, Ellen Ostenfeld.

Data curation: Roger Hesselstrand, Georgia Karabela, Efthymios Stavropoulos, Gikas Katsifis, George D. Kitas, Petros P. Sfikakis, Loukia Koutsogeorgopoulou.

Formal analysis: Konstantinos Bratis, Anthony Lindholm, Ellen Ostenfeld.

Writing – original draft: Konstantinos Bratis.

Writing – review & editing: Sophie Mavrogeni, Ellen Ostenfeld.

References

1. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969; 46(3):428–40. Epub 1969/03/01. https://doi.org/10.1016/0002-9343(69)90044-8 PMID: 5780367.

2. Botstein GR, LeRoy EC. Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features, pathogenesis, and new therapeutic approaches. Am Heart J. 1981; 102(5):913–9. Epub 1981/11/01. https://doi.org/10.1016/0002-8703(81)90043-0 PMID: 7030042.

3. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheumatic diseases clinics of North America. 1996; 22(4):841–60. Epub 1996/11/01. PMID: 8923599.

4. Steen VD, Medsger TA Jr., Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43(11):2437–44. Epub 2000/11/18. https://doi.org/10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U PMID: 11083266.

5. Follansbee WP, Miller TR, Curtiss EI, Orije JE, Bernstein RL, Kiernan JM, et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol. 1990; 17(5):656–62. Epub 1990/05/01. PMID: 2359076.

6. Dinser R, Ferrix M, Meier FM, Klingen K, Roll A. Endocardial and myocardial involvement in systemic sclerosis—is there a relevant inflammatory component? Joint, bone, spine: revue du rhumatisme. 2013; 80(3):320–3. Epub 2012/12/15. https://doi.org/10.1016/j.jbspin.2012.10.009 PMID: 23238003.

7. Kobayashi H, Yokoe I, Hirano M, Nakamura T, Nakajima Y, Fontaine KR, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009; 36(1):106–12. Epub 2008/12/02. https://doi.org/10.3899/jrheum.080377 PMID: 19040307.

8. Alexander EL, Firestein GS, Weiss JL, Heuser RR, Letil G, Wagner HN Jr., et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986; 105(5):661–8. Epub 1986/11/01. https://doi.org/10.7326/0003-4819-105-5-661 PMID: 3767147.

9. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clinical and experimental rheumatology. 2010; 28(5 Suppl 62):S48–53. Epub 2010/11/26. PMID: 21050545.

10. Kahan A, Nitenberg A, Foult JM, Amor B, Menkes CJ, Devaux JY, et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum. 1985; 28(6):637–46. Epub 1985/06/01. https://doi.org/10.1002/art.1780280607 PMID: 4004974.

11. Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis. 1997; 56(6):393–4. Epub 1997/06/01. https://doi.org/10.1136/ard.56.6.393 PMID: 9227172.

12. Perera A, Fertig N, Lucas M, Rodríguez-Reyna TS, Hu P, Steen VD, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum. 2007; 56(8):2740–6. Epub 2007/08/01. https://doi.org/10.1002/art.22747 PMID: 17665460.

13. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993; 125(1):194–203. Epub 1993/01/01. https://doi.org/10.1016/0002-8703(93)00075-k PMID: 8417518.

14. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010; 69(1):218–21. Epub 2009/03/13. https://doi.org/10.1136/ard.2008.103382 PMID: 19279015.
15. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 2002; 81(2):139–53. Epub 2002/03/13. https://doi.org/10.1097/00005792-200203000-00004 PMID: 11889413.

16. Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Seminars in arthritis and rheumatism. 2014; 43(4):526–35. Epub 2013/08/13. https://doi.org/10.1016/j.semarthrit.2013.07.006 PMID: 23932313.

17. Mavrogeni SI, Bratis K, Karabellia G, Spiliotis G, Wijk K, Hautemann D, et al. Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. Inflammation & allergy drug targets. 2015; 14(1):29–36. Epub 2015/09/17. PMID: 26374223.

18. Hor KN, Baumann R, Pedrizetti G, Tonti G, Gottliebson WM, Taylor M, et al. Magnetic resonance derived myocardial strain assessment using feature tracking. Journal of visualized experiments: JoVE. 2011/03/05. https://doi.org/10.3791/2356 PMID: 21372778.

19. Maret E, Todt T, Brudin L, Nylander E, Swahn E, Ohlsson JL, et al. Functional measurements based on feature tracking of cine magnetic resonance images identify left ventricular segments with myocardial scar. Cardiovasc Ultrasound. 2009; 7:53. Epub 2009/11/18. https://doi.org/10.1186/1476-7120-7-53 PMID: 19917130.

20. Kobayashi Y, Kobayashi H, J TG, Yokoe I, Hirano M, Nakajima Y, et al. Detection of Left Ventricular Regional Dysfunction and Myocardial Abnormalities Using Complementary Cardiac Magnetic Resonance Imaging in Patients with Systemic Sclerosis without Cardiac Symptoms: A Pilot Study. Internal medicine (Tokyo, Japan). 2016; 55(3):237–43. Epub 2016/02/03. https://doi.org/10.2169/internalmedicine.55.4441 PMID: 26831016.

21. van den Hoogen F, Khamma D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72(11):1747–55. Epub 2013/10/05. https://doi.org/10.1136/annrheumdis-2013-204424 PMID: 24092682.

22. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202–5. Epub 1988/02/01. PMID: 3361530.

23. Kanski M, Arshed H, Wuttge DM, Bozovic G, Hesselstrand R, Ugander M. Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals—a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2013; 15:86. Epub 2013/09/27. https://doi.org/10.1186/1532-429x-15-86 PMID: 24066703.

24. Gyllenhammar T, Kanski M, Engblom H, Wuttge DM, Carlsson M, Hesselstrand R, et al. Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study. BMC cardiovascular disorders. 2018; 18(1):16. Epub 2018/02/01. https://doi.org/10.1186/s12872-018-0756-x PMID: 29382301.

25. Steding K, Engblom H, Buhre T, Carlsson M, Mosen H, Wohlfart B, et al. Relation between cardiac dimensions and peak oxygen uptake. J Cardiovasc Magn Reson. 2010; 12:8. Epub 2010/02/04. https://doi.org/10.1186/1532-429x-12-8 PMID: 20122149.

26. Mangion K, Clerfond G, McComb C, Carrick D, Rauhalaarri SM, McClure J, et al. Myocardial strain in healthy adults across a broad age range as revealed by cardiac magnetic resonance imaging at 1.5 and 3.0T: Associations of myocardial strain with myocardial region, age, and sex. J Magn Reson Imaging. 2016; 44(5):1197–205. Epub 2016/04/23. https://doi.org/10.1002/jmri.25280 PMID: 27104306.

27. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23(7):685–713; quiz 86–8. Epub 2010/07/14. https://doi.org/10.1016/j.echo.2010.05.010 PMID: 20620859.

28. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30(20):2493–537. Epub 2009/08/29. https://doi.org/10.1093/eurheartj/ehp297 PMID: 19713419.

29. Zlatanovic M, Tadic M, Celic V, Ivanovic B, Stevanovic A, Damjanov N. Cardiac mechanics and heart rate variability in patients with systemic sclerosis: the association that we should not miss. Rheumatology international. 2017; 37(1):49–57. https://doi.org/10.1007/s00296-016-3618-9 PMID: 27888320.
30. Wenzel RR, Allegranza G, Bingelli C, Shaw S, Weidmann P, Luscher TF, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol. 1997; 29(7):1607–14. https://doi.org/10.1016/s0735-1097(97)00095-8 PMID: 9180126.

31. Tadic M, Zlatanovic M, Cuspidi C, Ivanovic B, Stevanovic A, Damjanov N, et al. The relationship between left ventricular deformation and heart rate variability in patients with systemic sclerosis: Two- and three-dimensional strain analysis. Int J Cardiol. 2017; 236:145–50. https://doi.org/10.1016/j.ijcard.2017.02.043 PMID: 28222894.

32. Hromadka M, Seidlerova J, Suchy D, Rajdl D, Lhotsky J, Ludvik J, et al. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients—Relationship with biochemical and echocardiography parameters. Int J Cardiol. 2017; 249:448–53. https://doi.org/10.1016/j.ijcard.2017.08.072 PMID: 28935460.

33. Kramer J, Niemann M, Liu D, Hu K, Machann W, Beer M, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J. 2013; 34(21):1587–96. Epub 2013/03/23. https://doi.org/10.1093/eurheartj/eht1098 PMID: 23520186.

34. Tsuji T, Tanaka H, Matsumoto K, Miyoshi T, Hiraishi M, Kaneko A, et al. Capability of three-dimensional speckle tracking radial strain for identification of patients with cardiac sarcoidosis. Int J Cardiovasc Imaging. 2013; 29(2):317–24. Epub 2012/08/02. https://doi.org/10.1007/s10554-012-1040-7 PMID: 22850930.

35. Ntusi NA, Piekchnik SK, Francis JM, Ferreira VM, Rai AB, Matthews PM, et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2014; 16:21. Epub 2014/03/07. https://doi.org/10.1186/1532-429X-16-21 PMID: 24593856.

36. Mukherjee M, Chung SE, Ton VK, Tedford RJ, Hummers LE, Wigley FM, et al. Unique Abnormalities in Cardiac and Peripheral Sympathetic Nervous System by Nifedipine: Role of Pharmacokinetics. J Am Coll Cardiol. 1997; 29(7):1607–14. https://doi.org/10.1016/s0735-1097(97)00095-8 PMID: 9180126.

37. Faccini A, Franchini S, Sabbadini MG, Camici PG. Cardiac involvement at rest in patients with systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2005; 6(6):407–18. Epub 2005/11/19. https://doi.org/10.1016/j.ejeca.2005.01.002 PMID: 16293527.

38. Castillo E, Lima JA, Blumerke DA. Regional myocardial function: advances in MR imaging and analysis. Radiographics: a review publication of the Radiological Society of North America, Inc. 2003; 23 Spec No:S127–40. Epub 2003/10/15. https://doi.org/10.1148/rg.23s1035512 PMID: 14557057.

39. Schuster A, Kutty S, Padiyath A, Parish V, Gribben P, Danford DA, et al. Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress. J Cardiovasc Magn Reson. 2011; 13:58. Epub 2011/10/14. https://doi.org/10.1186/1532-429X-13-58 PMID: 21992220.

40. Pedrizetti G, Claus P, Kilner PJ, Nagel E. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson. 2016; 18(1):51. Epub 2016/08/27. https://doi.org/10.1186/s12968-016-0269-7 PMID: 27561421.

41. Morton G, Schuster A, Jogia R, Kutty S, Beerbaum P, Nagel E. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. J Cardiovasc Magn Reson. 2012; 14:43. Epub 2012/06/23. https://doi.org/10.1186/1532-429X-14-43 PMID: 22721175.
46. Claus P, Omar AM, Pedrizzetti G, Sengupta PP, Nagel E. Tissue Tracking Technology for Assessing Cardiac Mechanics: Principles, Normal Values, and Clinical Applications. JACC Cardiovascular Imaging. 2015; 8(12):1444–60. Epub 2015/12/25. https://doi.org/10.1016/j.jcmg.2015.11.001 PMID: 26699113.

47. Wu L, Germans T, Guclu A, Heymans MW, Allaart CP, van Rossum AC. Feature tracking compared with tissue tagging measurements of segmental strain by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014; 16:10. Epub 2014/01/24. https://doi.org/10.1186/1532-429X-16-10 PMID: 24450803.

48. Claus P, Omar AMS, Pedrizzetti G, Sengupta PP, Nagel E. Tissue Tracking Technology for Assessing Cardiac Mechanics: Principles, Normal Values, and Clinical Applications. JACC Cardiovascular Imaging. 2015; 8(12):1444–60. Epub 2015/12/25. https://doi.org/10.1016/j.jcmg.2015.11.001 PMID: 26699113.

49. Farsalinos KE, Daraban AM, Unlu S, Thomas JD, Badano LP, Voigt JU. Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography. 2015; 28(10):1171–81.e2. Epub 2015/07/27. https://doi.org/10.1016/j.echo.2015.06.011 PMID: 26209911.

50. Mirea O, Pagourelis ED, Duchenne J, Bogaert J, Thomas JD, Badano LP, et al. Variability and Reproducibility of Segmental Longitudinal Strain Measurement: A Report From the EACVI/ASE Strain Standardization Task Force. JACC Cardiovascular Imaging. 2018; 11(1):15–24. Epub 2017/05/22. https://doi.org/10.1016/j.jcmg.2017.01.027 PMID: 28528147.

51. Nordlund D, Klug G, Heiberg E, Koul S, Larsen TH, Hoffmann P, et al. Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. European heart journal cardiovascular Imaging. 2016; 17(7):744–53. Epub 2016/03/24. https://doi.org/10.1093/ehjci/jew027 PMID: 27002140.